Angiogenic peptides

Details Angiogenic peptides Angiogenic peptides

1993-03-24

1995-11-28

Warden, Jill

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

514 15, 514 17, 514 18, 530330, 530329, 530328, C07K 510, C07K 706, A61K 3807, A61K 3808

Patent

active

054708311

ABSTRACT:
The present invention relates to peptides and peptide derivatives related to platelet factor 4 which exhibit angiogenic activity, to pharmaceutical compositions comprising said peptides, and to methods for promoting angiogenesis utilizing said peptides. It is based, in part, on the discovery that an octapeptide derived from platelet factor 4 and seven structurally related peptides (depicted in FIG. 1) are capable of inducing an angiogenic response in vivo as measured by neovascularization in rabbit corneal implant assay and by measurement of capillary endothelial cell chemoattraction. The angiogenic peptides of the invention may be particularly useful in promoting wound healing, including incisional healing, bone repair, burn healing, and post-infarction repair in myocardial injury, and in facilitating the assimilation of grafted tissues, particularly in persons suffering from vascular insufficiency, such as diabetic patients.

REFERENCES:
patent: 4645828 (1987-02-01), Twardzik et al.
Cortellaro et al., 1990, Thrombosis Res. 58:571-576.
Eisman et al., 1990, Blood, vol. 76, No. 2 (Jul. 15), pp. 336-344.
Medici et al., 1989, Thrombosis Res. 54:277-287.
Rybak et al., 1989, Blood, vol. 73, No. 6 (May 1), pp. 1534-1539.
Zucker et al., 1989, Proc. Natl. Acad. Sci. USA 86:7571-7574.
Bebawy et al., 1986, J. Leukocyte Biol. 39:423-434.
Guastamacchia et al., 1985, Boll. Soc. It. Biol., No. 4, vol. LXI, pp. 499-505.
Schmitz-Huebner et al., 1984, Thrombosis Res. 34:277-285.
Weerasinghe et al., 1984, Thrombosis Res. 33:625-631.
Banda et al., 1982, Proc. Natl. Acad. Sci. USA 79:7773-7777.
Bernstein et al., 1982, J. Cell. Sci. 56:71-82.
Gimbrone, Jr., et al., 1974, J. Natl. Cancer Institute, vol. 52, No. 2, pp. 413-427.
Aoyagi et al., 1988, "Interaction of basic extension peptide fragments of adrenodixon precursor with phospholipid vesicles", Int. J. Peptide Protein Res. 32:406-414.
V. LaRussa et al.; "Effects of Anti-CD33 Blocked Ricin Immunotoxin on the Capacity of CD34 Human Marrow Cells to Establish in vitro Hematopoiesis in Long-term Marrow Cultures" Exp. Hematol., 20:442-448 (1992).
A. Engert et al.; "Resistance of Myeloid Leukaemia CE11 Lines to Ricin A-Chain Immunotoxins" Leukemia Research 15:1079-1086, No. 15 (1991).
J. Lambert et al.; "An Immunotoxin Prepared with Blocked Ricin: A Natural Plant Toxin Adapted for Therapeutic Use" Cancer Research, 51:6236-6242 (1991).
D. Roy et al.; "Anti-MY9-Block-Ricin: An Immunotoxin for Selective Targeting of Acute Myeloid Leukemia Cells" Blood, 77:2404-2412 (1991).
Ciaglowski et al. Arch. Biochem. Biophys. vol. 250 No. 1 (1986) 249-256.

Affiliated with

Also associated with

Rating

Angiogenic peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Angiogenic peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Angiogenic peptides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2013708